253 related articles for article (PubMed ID: 28112685)
1. Chemogenetic stimulation of striatal projection neurons modulates responses to Parkinson's disease therapy.
Alcacer C; Andreoli L; Sebastianutto I; Jakobsson J; Fieblinger T; Cenci MA
J Clin Invest; 2017 Feb; 127(2):720-734. PubMed ID: 28112685
[TBL] [Abstract][Full Text] [Related]
2. Differential Synaptic Remodeling by Dopamine in Direct and Indirect Striatal Projection Neurons in Pitx3
Suarez LM; Alberquilla S; García-Montes JR; Moratalla R
J Neurosci; 2018 Apr; 38(15):3619-3630. PubMed ID: 29483281
[TBL] [Abstract][Full Text] [Related]
3. L-DOPA Oppositely Regulates Synaptic Strength and Spine Morphology in D1 and D2 Striatal Projection Neurons in Dyskinesia.
Suarez LM; Solis O; Aguado C; Lujan R; Moratalla R
Cereb Cortex; 2016 Oct; 26(11):4253-4264. PubMed ID: 27613437
[TBL] [Abstract][Full Text] [Related]
4. Diametric neural ensemble dynamics in parkinsonian and dyskinetic states.
Parker JG; Marshall JD; Ahanonu B; Wu YW; Kim TH; Grewe BF; Zhang Y; Li JZ; Ding JB; Ehlers MD; Schnitzer MJ
Nature; 2018 May; 557(7704):177-182. PubMed ID: 29720658
[TBL] [Abstract][Full Text] [Related]
5. Modulation of direct pathway striatal projection neurons by muscarinic M₄-type receptors.
Hernández-Flores T; Hernández-González O; Pérez-Ramírez MB; Lara-González E; Arias-García MA; Duhne M; Pérez-Burgos A; Prieto GA; Figueroa A; Galarraga E; Bargas J
Neuropharmacology; 2015 Feb; 89():232-44. PubMed ID: 25290553
[TBL] [Abstract][Full Text] [Related]
6. Hyperactive Response of Direct Pathway Striatal Projection Neurons to L-dopa and D1 Agonism in Freely Moving Parkinsonian Mice.
Sagot B; Li L; Zhou FM
Front Neural Circuits; 2018; 12():57. PubMed ID: 30104963
[TBL] [Abstract][Full Text] [Related]
7. L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.
Suárez LM; Solís O; Caramés JM; Taravini IR; Solís JM; Murer MG; Moratalla R
Biol Psychiatry; 2014 May; 75(9):711-22. PubMed ID: 23769604
[TBL] [Abstract][Full Text] [Related]
8. Striatonigral neurons divide into two distinct morphological-physiological phenotypes after chronic L-DOPA treatment in parkinsonian rats.
Fieblinger T; Zanetti L; Sebastianutto I; Breger LS; Quintino L; Lockowandt M; Lundberg C; Cenci MA
Sci Rep; 2018 Jul; 8(1):10068. PubMed ID: 29968767
[TBL] [Abstract][Full Text] [Related]
9. Striatal Direct Pathway Targets Npas1
Cui Q; Du X; Chang IYM; Pamukcu A; Lilascharoen V; Berceau BL; García D; Hong D; Chon U; Narayanan A; Kim Y; Lim BK; Chan CS
J Neurosci; 2021 May; 41(18):3966-3987. PubMed ID: 33731445
[TBL] [Abstract][Full Text] [Related]
10. Differential enhancement of ERK, PKA and Ca
Mariani LL; Longueville S; Girault JA; Hervé D; Gervasi N
Neurobiol Dis; 2019 Oct; 130():104506. PubMed ID: 31220556
[TBL] [Abstract][Full Text] [Related]
11. The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model.
Yin LL; Geng XC; Zhu XZ
Brain Res Bull; 2011 Nov; 86(5-6):367-72. PubMed ID: 21963945
[TBL] [Abstract][Full Text] [Related]
12. Chemogenetic Targeting of Dorsomedial Direct-pathway Striatal Projection Neurons Selectively Elicits Rotational Behavior in Mice.
Bay Kønig A; Ciriachi C; Gether U; Rickhag M
Neuroscience; 2019 Mar; 401():106-116. PubMed ID: 30668973
[TBL] [Abstract][Full Text] [Related]
13. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
[TBL] [Abstract][Full Text] [Related]
14. Striatal inhibition of calpains prevents levodopa-induced neurochemical changes and abnormal involuntary movements in the hemiparkinsonian rat model.
Chagniel L; Robitaille C; Lebel M; Cyr M
Neurobiol Dis; 2012 Jan; 45(1):645-55. PubMed ID: 22037042
[TBL] [Abstract][Full Text] [Related]
15. (6aR)-11-amino-N-propyl-noraporphine, a new dopamine D2 and serotonin 5-HT1A dual agonist, elicits potent antiparkinsonian action and attenuates levodopa-induced dyskinesia in a 6-OHDA-lesioned rat model of Parkinson's disease.
Zhao R; Lu W; Fang X; Guo L; Yang Z; Ye N; Zhao J; Liu Z; Jia J; Zheng L; Zhao B; Zhang A; Zhen X
Pharmacol Biochem Behav; 2014 Sep; 124():204-10. PubMed ID: 24955866
[TBL] [Abstract][Full Text] [Related]
16. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
[TBL] [Abstract][Full Text] [Related]
17. Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
Pinna A; Ko WK; Costa G; Tronci E; Fidalgo C; Simola N; Li Q; Tabrizi MA; Bezard E; Carta M; Morelli M
Mov Disord; 2016 Apr; 31(4):501-11. PubMed ID: 26871939
[TBL] [Abstract][Full Text] [Related]
18. Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia.
Bézard E; Muñoz A; Tronci E; Pioli EY; Li Q; Porras G; Björklund A; Carta M
Neurosci Res; 2013 Dec; 77(4):242-6. PubMed ID: 24135129
[TBL] [Abstract][Full Text] [Related]
19. M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia.
Shen W; Plotkin JL; Francardo V; Ko WK; Xie Z; Li Q; Fieblinger T; Wess J; Neubig RR; Lindsley CW; Conn PJ; Greengard P; Bezard E; Cenci MA; Surmeier DJ
Neuron; 2015 Nov; 88(4):762-73. PubMed ID: 26590347
[TBL] [Abstract][Full Text] [Related]
20. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
